Theragen Etex
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Theragen Etex makes prescription and over-the-counter medicines and also provides genomic analysis services, sequencing DNA and decoding RNA variations to help understand genetic information.
Its pharmaceutical products are used in clinical and consumer health settings, while its genomic services are supplied to research and health-care customers. Listed on KOSDAQ, Korea's tech and small-cap board, the company operates two distinct business divisions, pharmaceuticals and genomic analysis, alongside new-drug research and development.
Summary is AI-generated and may contain errors · figures from DART filings
Its genomic analysis operations extend beyond Korea through overseas entities established specifically to expand DNA and RNA sequencing services into China, including Beijing-based and Hong Kong-registered subsidiaries named in its filing.
Theragen Etex in five facts
What does Theragen Etex do?
Theragen Etex makes prescription and over-the-counter medicines and also provides genomic analysis services, sequencing DNA and decoding RNA variations to help understand genetic information.
Where is Theragen Etex listed and in which sector?
Theragen Etex (Korean name: 테라젠이텍스) trades under KRX code 066700 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Theragen Etex?
Its market capitalisation was US$56.6M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Theragen Etex's latest annual revenue and operating profit?
For fiscal year 2025, Theragen Etex reported revenue of US$205M, operating profit of US$7.7M and net income of US$8.9M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 8.8% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Conversion price adjustmentOct 19
- Report on securities held by executives/major shareholdersOct 19
- Share cancellation decisionSep 29
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Theragen Etex reported consolidated results for FY2025: revenue of US$190M (+8.8% year on year), operating profit of US$7.16M (−18.3% year on year) and net income of US$8.23M (from a loss a year earlier).
Earnings · Feb 26